⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

RNTX News

Rein Therapeutics, Inc. Common Stock

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis